ATE184914T1 - Erythropoietin- analoge - Google Patents

Erythropoietin- analoge

Info

Publication number
ATE184914T1
ATE184914T1 AT95101849T AT95101849T ATE184914T1 AT E184914 T1 ATE184914 T1 AT E184914T1 AT 95101849 T AT95101849 T AT 95101849T AT 95101849 T AT95101849 T AT 95101849T AT E184914 T1 ATE184914 T1 AT E184914T1
Authority
AT
Austria
Prior art keywords
erythropoietin
epo
isoforms
thr125
gps
Prior art date
Application number
AT95101849T
Other languages
English (en)
Inventor
Thomas Edward Byrne
Steven George Elliott
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23670537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE184914(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Application granted granted Critical
Publication of ATE184914T1 publication Critical patent/ATE184914T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95101849T 1989-10-13 1990-10-12 Erythropoietin- analoge ATE184914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42144489A 1989-10-13 1989-10-13
PCT/US1990/005758 WO1991005867A1 (en) 1989-10-13 1990-10-09 Erythropoietin isoforms

Publications (1)

Publication Number Publication Date
ATE184914T1 true ATE184914T1 (de) 1999-10-15

Family

ID=23670537

Family Applications (2)

Application Number Title Priority Date Filing Date
AT90311193T ATE146187T1 (de) 1989-10-13 1990-10-12 Erythropoietin-isoformen
AT95101849T ATE184914T1 (de) 1989-10-13 1990-10-12 Erythropoietin- analoge

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT90311193T ATE146187T1 (de) 1989-10-13 1990-10-12 Erythropoietin-isoformen

Country Status (23)

Country Link
EP (2) EP0668351B1 (de)
JP (2) JP2983629B2 (de)
KR (2) KR100263845B1 (de)
CN (1) CN1063796C (de)
AT (2) ATE146187T1 (de)
AU (1) AU646822B2 (de)
CA (2) CA2027635C (de)
CZ (4) CZ291515B6 (de)
DE (2) DE69029370C5 (de)
DK (2) DK0668351T3 (de)
ES (2) ES2139764T3 (de)
FI (1) FI105688B (de)
GR (2) GR3022658T3 (de)
HK (1) HK1006718A1 (de)
IE (1) IE903663A1 (de)
IL (3) IL95971A0 (de)
LV (1) LV12575B (de)
NO (1) NO301832B1 (de)
NZ (1) NZ235676A (de)
PT (1) PT95586B (de)
SK (1) SK284429B6 (de)
WO (1) WO1991005867A1 (de)
ZA (1) ZA908166B (de)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
EP1731174A3 (de) * 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptide mit durch Hydrazon oder Oxim Gruppe kovalent gebunden N-terminalen Polyethylen-glycol
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU753106B2 (en) 1998-04-22 2002-10-10 Cornell Research Foundation Inc. Canine erythropoietin gene and recombinant protein
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
DE69935345T3 (de) * 1998-10-23 2018-03-01 Amgen Inc. Methoden und zusammensetzungen zur prävention und behandlung der anämie
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
BR9905868A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
AU5551601A (en) 2000-04-21 2001-11-07 Amgen Inc Methods and compositions for the prevention and treatment of anemia
AU2001276737A1 (en) 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP1382964A4 (de) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd Verfahren zur tensid-quantifizierung
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US20070066568A1 (en) 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
DE20321793U1 (de) 2002-09-11 2010-06-02 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Derivate
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
WO2004032971A1 (en) 2002-10-08 2004-04-22 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN1897959A (zh) 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
EP1699821B1 (de) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
EP2336192A1 (de) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt.
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP3026109B1 (de) 2005-12-08 2022-03-09 Amgen Inc. Verbesserte herstellung von glykoproteinen unter verwendung von mangan
ES2434494T3 (es) 2005-12-08 2013-12-16 Amgen, Inc. Células huésped mejoradas y métodos de cultivo
WO2007083683A1 (ja) * 2006-01-18 2007-07-26 Chugai Seiyaku Kabushiki Kaisha シアル酸の除去方法及びアシアロエリスロポエチンの製造方法
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
CN101460188B (zh) 2006-06-07 2013-09-04 国立大学法人德岛大学 使用促红细胞生成素的局部缺血疾病的治疗
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP2498096A1 (de) 2006-07-21 2012-09-12 Amgen Inc. Verfahren zum Erkennen und/oder Messen von Hepcidin in einer Probe
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
EP2057997A4 (de) 2006-08-22 2012-11-07 Chugai Pharmaceutical Co Ltd Mittel zur prävention und/oder behandlung von peripherer neuropathie
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
DK2081956T3 (da) 2006-11-13 2013-06-24 Charite Universitaetsmedizin FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
EP2803675A3 (de) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin-Antikörper und Anwendungsverfahren
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EP2161031A1 (de) 2008-09-05 2010-03-10 SuppreMol GmbH Fc-gamma-Rezeptor zur Behandlung von B-Zellen-vermittelter multipler Sklerose
CA2736141C (en) 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
EP3009447B1 (de) 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Herstellung von erythropoesestimulierendem protein unter verwendung von metallionen
KR20120117728A (ko) 2009-09-23 2012-10-24 바이오제너릭스 에이지 재조합 인간 에리트로포이에틴(ｅｐｏ)의 정제 방법, 이렇게 정제된 ｅｐｏ 및 이를 포함하는 약학적 조성물
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
EP3045187B1 (de) 2011-10-14 2019-04-10 Amgen Inc. Injektor und verfahren zur montage
US20150065689A1 (en) * 2012-04-10 2015-03-05 Dr. Reddy's Laboratories Limited Single step fractionation method
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
EP3733170A1 (de) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Verfahren zur behandlung von androgenrezeptor(ar)-positivem brustkrebs mit selektivem androgenrezeptormodulator (sarms)
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
EP3524691A1 (de) 2012-12-07 2019-08-14 SuppreMol GmbH Schichtung und behandlung von patienten von idiopathischer thrombozytopenischer purpura
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
EP3060275B1 (de) 2013-10-24 2019-07-03 Amgen Inc. Injektor und verfahren zur montage
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3689394A1 (de) 2014-12-19 2020-08-05 Amgen Inc. Arzneimittelabgabevorrichtung mit live-knopf oder benutzerschnittstellenfeld
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (de) 2016-07-01 2025-03-12 Amgen Inc. Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127B1 (de) 2016-10-25 2026-04-08 Amgen Inc. Injektor mit körperkontakt
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP3658206A1 (de) 2017-07-25 2020-06-03 Amgen Inc. Arzneimittelabgabevorrichtung mit behälterzugangssystem und zugehörigem verfahren zur montage
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (de) 2017-08-18 2026-02-18 Amgen Inc. Tragbarer injektor mit sterilem klebepatch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (de) 2017-10-04 2023-02-08 Amgen Inc. Durchflussadapter für arzneimittelabgabevorrichtung
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3958934B1 (de) 2019-04-24 2025-04-09 Amgen Inc. Anordnungen und verfahren zur überprüfung der sterilisation von spritzen
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CU24704B1 (es) * 2019-09-05 2024-04-08 Ct Inmunologia Molecular Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
JP2025536587A (ja) 2022-11-02 2025-11-07 エフ． ホフマン－ラ ロシュ アーゲー 糖タンパク質組成物を生産するための方法
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2354793A1 (fr) * 1976-06-14 1978-01-13 Gresset Bernard Jouet tel que tableau
FR2475988A2 (fr) * 1978-09-04 1981-08-21 Cassagnes Andre Appareil a dessiner
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
ATE146187T1 (de) 1996-12-15
PT95586A (pt) 1991-09-30
FI912829A0 (fi) 1991-06-12
IL125175A0 (en) 1999-03-12
EP0428267A2 (de) 1991-05-22
PT95586B (pt) 1997-08-29
CA2027635C (en) 2001-12-04
EP0428267B2 (de) 2004-12-08
JP2983629B2 (ja) 1999-11-29
FI105688B (fi) 2000-09-29
KR100263845B1 (ko) 2000-08-16
CZ291515B6 (cs) 2003-03-12
CZ497290A3 (cs) 2000-08-16
HK1010398A1 (en) 1999-06-17
ES2097753T3 (es) 1997-04-16
IE903663A1 (en) 1991-04-24
DE69029370T3 (de) 2006-02-23
DK0428267T4 (da) 2005-03-14
JP3073905B2 (ja) 2000-08-07
DE69033301T2 (de) 2000-04-20
ZA908166B (en) 1991-08-28
IL95971A0 (en) 1991-07-18
DK0668351T3 (da) 1999-12-20
SK284429B6 (sk) 2005-04-01
EP0428267B1 (de) 1996-12-11
AU6604290A (en) 1991-05-16
KR100221066B1 (ko) 1999-10-01
NO301832B1 (no) 1997-12-15
ES2097753T5 (es) 2005-07-01
GR3032089T3 (en) 2000-03-31
LV12575A (en) 2000-11-20
NO912281D0 (no) 1991-06-13
EP0668351A1 (de) 1995-08-23
CZ291472B6 (cs) 2003-03-12
CN1063796C (zh) 2001-03-28
DE69029370C5 (de) 2010-03-25
WO1991005867A1 (en) 1991-05-02
GR3022658T3 (en) 1997-05-31
AU646822B2 (en) 1994-03-10
EP0668351B1 (de) 1999-09-22
DE69029370T2 (de) 1997-06-05
EP0428267A3 (en) 1991-08-14
HK1006718A1 (en) 1999-03-12
DE69029370D1 (de) 1997-01-23
CZ291488B6 (cs) 2003-03-12
NO912281L (no) 1991-06-13
JPH04502331A (ja) 1992-04-23
SK497290A3 (en) 2000-12-11
ES2139764T3 (es) 2000-02-16
LV12575B (en) 2001-03-20
CN1051936A (zh) 1991-06-05
IL125175A (en) 2004-07-25
DE69033301D1 (de) 1999-10-28
CA2027635A1 (en) 1991-04-14
NZ235676A (en) 1992-04-28
KR920701255A (ko) 1992-08-11
CA2165694A1 (en) 1991-04-14
CA2165694C (en) 2003-03-18
DK0428267T3 (da) 1997-06-09
CZ291471B6 (cs) 2003-03-12
JPH08151398A (ja) 1996-06-11

Similar Documents

Publication Publication Date Title
DK0668351T3 (da) Erythropoietinanaloger
AU590896B2 (en) Improved formulations for recombinant beta-interferon
DK0473724T3 (da) Et humant cytokin, interleukin-9
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
IT8119760A0 (it) Polipeptide prodotto microbiologicamente con la sequenza di aminoacidi dell'interferone umano, dna e plasmidi che codificano per questa sequenza, microorganismi che contengono queste informazioni genetiche e processo per la loro preparazione.
MY101887A (en) A novel human physiologically active polypeptide.
ATE256182T1 (de) Neuartiges p- selectin ligandenprotein
ATE195344T1 (de) Gereinigtes interleukin-1 und für interleukin-1 kodierende dns und deren herstellung, solche dns enthaltende vektoren und deren herstellung und verwendung zum transformieren von wirten, die die expression von interleukin-1 zulassen
GR852622B (de)
AU2308992A (en) Cysteine depleted il-6 muteins
HUT50195A (en) New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
NO873437L (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
AU637589B2 (en) Ancrod proteins, their production and use
EP0211321A3 (de) Aminosäurezusammensetzung, Verfahren zu deren Herstellung und diese enthaltende medizinische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time